https://www.nature.com/articles/s41591-018-0040-8
"... Adoptive transfer of these mutant-protein-specific TILs in conjunction with interleukin (IL)-2 and checkpoint blockade mediated the complete durable regression of metastatic breast cancer, which is now ongoing for >22 months, and it represents a new immunotherapy approach for the treatment of these patients. ..."
Кратко по-русски:
https://www.bbc.com/russian/news-44361532
"... Adoptive transfer of these mutant-protein-specific TILs in conjunction with interleukin (IL)-2 and checkpoint blockade mediated the complete durable regression of metastatic breast cancer, which is now ongoing for >22 months, and it represents a new immunotherapy approach for the treatment of these patients. ..."
Кратко по-русски:
https://www.bbc.com/russian/news-44361532